Atomic force microscopy to study molecular mechanisms of amyloid fibril formation and toxicity in Alzheimer's disease

Drug Metabolism Reviews

Volumn 46, Issue 2, 2014, Pages 207-223

  Drolle, Elizabeth ^a,b   Hane, Francis ^a   Lee, Brenda ^a   Leonenko, Zoya ^a,b  

^a UNIVERSITY OF WATERLOO   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Alzheimer's disease; Amyloid; Amyloid toxicity; Atomic force microscopy; Cholesterol; Lipid membrane; Molecular mechanism; Nanotechnology

Indexed keywords

AMYLOID; CHOLESTEROL; ION CHANNEL; AMYLOID BETA PROTEIN; MEMBRANE LIPID;

ALZHEIMER DISEASE; ATOMIC FORCE MICROSCOPY; BRAIN TOXICITY; HUMAN; LIPID COMPOSITION; LIPID MEMBRANE; NANOTECHNOLOGY; REVIEW; STATIC ELECTRICITY; SURFACE PROPERTY; AMYLOID PLAQUE; CELL MEMBRANE; METABOLISM; MOLECULAR DYNAMICS; NERVE CELL; PATHOLOGY; TOXICITY; ULTRASTRUCTURE;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; CELL MEMBRANE; HUMANS; ION CHANNELS; MEMBRANE LIPIDS; MEMBRANE MICRODOMAINS; MICROSCOPY, ATOMIC FORCE; MOLECULAR DYNAMICS SIMULATION; NEURONS; PLAQUE, AMYLOID;

EID: 84899446567     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2014.882354     Document Type: Review

References (175)

1. Abramov AY, Ionov M, Pavlov E, Duchen MR. (2011). Membrane cholesterol content plays a key role in the neurotoxicity of b-amyloid: implications for Alzheimer's disease. Aging Cell 10: 595-603.
2. Abu-Hamad S, Arbel N, Calo D, et al. (2009). The VDAC1 N-terminus is essential both for apoptosis and the protective effect of antiapoptotic proteins. J Cell Sci 122: 1906-1916.
3. Adamcik J, Jung J-M, Flakowski J, et al. (2010). Understanding amyloid aggregation by statistical analysis of atomic force microscopy images. Nat Nanotechnol 5: 423-428.
4. Ahyayauch H, Raab M, Busto JV, et al. (2013). Binding of b-amyloid (1-42) peptide to negatively charged phospholipid membranes in the liquid-ordered state: Modeling and experimental studies. Biophys J 103: 453-463.
5. Allsop D, Landon M, Kidd M. (1983). The isolation and amino acid composition of senile plaque core protein. Brain Res 259: 348-352.
6. Alzheimer A. (1907). Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-gerichtliche Medizin 64: 146-148.
7. Ambroggio EE, Kim DH, Separovic F, et al. (2005). Surface behaviour and lipid interaction of Alzheimer beta-amyloid peptide 1-42: A membrane-disrupting peptide. Biophys J 88: 2706-2713.
8. Antzutkin ON, Balbach JJ, Leapman RD, et al. (2000). Multiple quantum solid-state NMR indicates a parallel, not antiparallel, organization of beta-sheets in Alzheimer's beta-amyloid fibrils. PNAS 97:13045-13050.
9. Arispe N, Rojas E, Pollard HB. (1993). Alzheimer disease amyloid b protein forms calcium channels in bilayer membranes: Blockade by tromethamine and aluminum. PNAS 90: 567-571.
10. Arispe N, Doh M. (2002). Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease Abeta (1-40) and (1-42) peptides. FASEB 16: 1526-1536.
11. Arispe N. (2004). Architecture of the Alzheimer's abeta ion channel pore. J Mem Biol 197: 33-48.
12. Bartzokis G. (2004). Age-related myelin breakdown: A developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging 25: 5-18.
13. Bay DC, Court DA. (2002). Origami in the outer membrane: the transmembrane arrangement of mitochondrial porins. Biochem Cell Biol 80: 551-562.
14. Behl C, Davis JB, Lesley R, Schubert D. (1994). Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77: 817-827.
15. Benoit M, Gabriel D, Gerisch G, Gaub HE. (2000). Discrete interactions in cell adhesion measured by single-molecule force spectroscopy. Nature Cell Biol 2: 313-317.
16. Berhanu WM, Hansmann UH. (2012). Structure and dynamics of amyloid-b segmental polymorphisms. PLoS ONE 7:e41479.
17. Berthelot K, Cullin C, Lecomte S. (2013). What does make an amyloid toxic: Morphology, structure or interaction with membrane? Biochimie 95: 12-19.
18. Binning G, Quate CF, Gerber C. (1986). Atomic force microscope. Phys Rev Let 56: 930-933.
19. Bitan G, Kirkitadze MD, Lomakin A, et al. (2003). Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. PNAS 100: 330-335.
20. Blackley HK, Patel N, Davies MC, et al. (1999). Morphological development of b(1-40) amyloid fibrils. Exp Neurology 158: 437-443.
21. Blackley HK, Sanders GH, Davies MC, et al. (2000). In-situ atomic force microscopy study of beta-amyloid fibrillization. J Mol Biol 298: 833-840.
22. Bokvist M, Lindstrom, F, Watts A, Grobner, G. (2004). Two types of Alzheimer's b-amyloid (1-40) peptide membrane interactions: Aggregation preventing transmembrane anchoring versus accelerated surface fibril formation. J Mol Biol 335: 1039-1049.
23. Bonn M, Roke S, Berg O, et al. (2004). A vibrational study of cholesterol-lipid interactions in a monolayer: A molecular view of condensation. Phys Chem B 108: 19083-10985.
24. Brown CL, Aksay IA, Saville DA, Hecht MH. (2002). Template-directed assembly of a de novo designed protein. J Am Chem Soc 124: 6846-6848.
25. Bucciantini M, Giannoni E, Chiti F, et al. (2002). Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416: 507-511.
26. Buchsteiner A, Haub T, Dencher N. (2012). Influence of amyloid-b peptides with different lengths and amino acid sequences on the lateral diffusion of lipids in model membranes. Soft Matter 8: 424-429.
27. Buell AK, Dhulesia A, White DA, et al. (2012). Detailed analysis of the energy barriers for amyloid fibril growth. Angew Chemie 51: 5247-5251.
28. Burke KA, Yates EA, Legleiter J. (2013). Amyloid-forming proteins alter the local mechanical properties of lipid membranes. Biochemistry 525: 808-817.
29. Bush AI, Tanzi RE. (2008). Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 5: 421-432.
30. Butterfield DA, Yatin SM, Varadarajan S, Koppal, T. (1999). Amyloid beta-peptide-associated free radical oxidative stress, neurotoxicity, and Alzheimer's disease. Methods Enzymol 309: 746-768.
31. Cadenhead, G. (1985). Structure and properties of cell membranes. Boca Raton (FL): CRC Press.
32. Campioni S, Mannini B, Zampagni M, et al. (2010). A causative link between the the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol 6: 140-147.
33. Casadio R, Jacoboni I, Messina A, De Pinto V. (2002). A 3D model of the voltage-dependent anion channel (VDAC). FEBS Lett 520: 1-7.
34. Cecchi C, Nichino D, Zampagni M, et al. (2009). A protective role for lipid raft cholesterol against amyloid-induced membrane damage in human neuroblastoma cells. Biochim Biophys Acta 1788: 2204-2216.
35. Chiti F, Dobson CM. (2006). Protein misfolding, functional amyloid, and human disease. Annual Rev Biochem 75: 333-366.
36. Choo-Smith LP, Garzon-RodriguezW, Glabe CG, Surewicz WK. (1997). Acceleration of amyloid fibril formation by specific binding of Abeta- (1-40) peptide to ganglioside-containing membrane vesicles. J Biol Chem 272: 22987-22990.
37. Choucair A, Chakrapani M, Chakravarthy B, et al. (2007). Preferential accumulation of Abeta(1-42) on gel phase domains of lipid bilayers: an AFM and fluorescence study. Biochem Biophys Acta 1768: 146-154.
38. Connolly MR, Smith CG. (2010). Nanoanalysis of graphene layers using scanning probe techniques. Phil Trans Roy Soc London A 368: 5379-5389.
39. Cordy JM, Hooper NM, Turner AJ. (2006). The involvement of lipid rafts in Alzheimer's disease. Mol Memb Biol 23: 111-122.
40. Crespo R, Rocha FA, Damas AM, Martins PM. (2012). A generic crystallization-like model that describes the kinetics of amyloid fibril formation. J Biol Chem 287: 30585-30594.
41. Dahlgren KN, Manelli AM, Stine WB, et al. (2002). Oligomeric and fibrillar species of amyloid-b peptides differentially affect neuronal viability. J Biol Chem 277: 32046-32053.
42. Dante S, Haub T, Dencher NA. (2006). Cholesterol inhibits the insertion of the Alzheimer's peptide Ab(25-35) in lipid bilayers. Eur Biophys J 35: 523-531.
43. Davinelli S, Intrieri M, Russo C, et al. (2011). The "Alzheimer's disease signature": potential perspectives for novel biomarkers. Immun Aging 8: 7-17.
44. De Meyer G, Shapiro F, Vanderstichele H, et al. (2010). Diagnosisindependent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neuro 67: 949-956.
45. Demel RA, De Kruyff B. (1976). The function of sterols in membranes. Biochim Biophys Acta 457: 109-132.
46. Dobson CM. (2001). The structural basis of protein folding and its links with human disease. Phil Trans Roy Soc London B 356: 133-145.
47. Dobson CM, Karplus M. (1999). The fundamentals of protein folding: bringing together theory and experiment. Curr Opin Struc Biol 9:92-101.
48. Drolle E, Gaikwad R, Leonenko Z. (2012). Nanoscale electrostatic domains in cholesterol-laden lipid membranes create a target for amyloid binding. Biophys J 103:L27-L29.
49. Dyrks T, Dyrks E, Masters CL, Beyreuther K. (1993). Amyloidogenicity of rodent and human beta A4 sequences. FEBS Lett 324: 231-236.
50. Ege C, Majewski J, Wu G, et al. (2005). Templating effect of lipid membranes on Alzheimer's amyloid beta peptide. Chemphyschem 6: 226-229.
51. Esparza TJ, Zhao H, Cirrito JR, et al. (2013). Amyloid-b oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol 73: 104-119.
52. Farooqui AA, Liss L, Horrocks LA. (1988). Neurochemical aspects of Alzheimer's disease: Involvement of membrane phospholipids. Metab Brain Dis 3: 19-35.
53. Farooqui AA, Wells K, Horrocks LA. (1995). Breakdown of membrane phospholipids in Alzheimer disease. Mol Chem Neuropathol 25: 155-173.
54. Fassbender K, Masters C, Beyreuther, K. (2001). Alzheimer's disease: Molecular concepts and therapeutic targets. Naturwissenschaften 88: 261-267.
55. Finot E, Leonenko Y, Moores B, et al. (2010). Effect of cholesterol on electrostatics in lipid-protein films of a lung surfactant. Langmuir 26: 1929-1935.
56. Geng J, Zhao C, Ren J, Qu X. (2010). Alzheimer's disease amyloid beta converting left-handed Z-DNA back to right-handed B-form. Chem Comm 46: 7187-7189.
57. Giacomelli CE, Norde W. (2005). Conformational changes of the amyloid b-peptide (1-40) adsorbed on solid surfaces. Macromol Biosci 5: 401-407.
58. Giordani C, Wakai C, Yoshida K, et al. (2008). Cholesterol location and orientation in aqueous suspension of large unilamellar vesicles of phospholipid revealed by intermolecular nuclear Overhauser effect. J Phys Chem B 112: 2622-2628.
59. Glenner GG, Wong CW. (1984). Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890.
60. Goldsbury C, Kistler J, Aebi U, et al. (1999). Watching amyloid fibrils grow by time-lapse atomic force microscopy. J Mol Biol 285: 33-39.
61. Gorbenko G, Kinnunen P. (2006). The role of lipid-protein interactions in amyloid-type protein fibril formation. Chem Phys Lipids 141: 72-82.
62. Greenough MA, Camakaris J, Bush AI. (2012). Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochem Int 62: 540-555.
63. Gunasekara L, Schurch S, Schoel W, et al. (2005). Pulmonary surfactant function is abolished by an elevated proportion of cholesterol. Biochim Biophys Acta 1737: 27-35.
64. Hammarström P, Ali MM, Mishra R, et al. (2008). A catalytic surface for amyloid fibril formation. J Phys: Conf Ser 100:052039. doi:10.1088/ 1742-6596/100/5/052039.
65. Hane F, Drolle E, Gaikwad R, et al. (2011). Amyloid-b aggregation on model lipid membranes: An AFM study. J Alz Dis 26: 485-494.
66. Hane F, Tran G, Attwood SJ, Leonenko Z. (2013). Cu2+ affects amyloidb (1-42) aggregation by increasing peptide-peptide binding forces. PLoS ONE 8:e59005. DOI: 10.1371/journal.pone.0059005.
67. Hansma HG, Hoh JH. (1994). Biomolecular imaging with the atomic force microscope. Ann Rev Biophys Biomol Struct 23: 115-140.
68. Hardy J, Allsop D. (1991). Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12: 383-388.
69. Harper JD, Lieber CM, Lansbury Jr PT. (1997). Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-b protein. Chem Biol 4: 951-959.
70. Harper JD, Lansbury Jr PT. (1997). Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Ann Rev Biochem 66: 385-407.
71. Hinterdorfer P, Dufrene Y. (2006). Detection and localization of single molecular recognition events using atomic force microscopy. Nat Methods 3: 347-355.
72. Ionov M, Klajnert B, Gardikis K, et al. (2010). Effect of amyloid beta peptides Ab1-28 and Ab25-40 on model lipid membranes. J Therm Anal Calorim 99: 741-747.
73. Irwin JA, Wong HE, Inchan K. (2013). Different fates of Alzheimer's disease amyloid-b fibrils remodeled by biocompatible small molecules. Biomacromolecules 14: 264-274.
74. Jang H, Arce FT, Ramachandran S, et al. (2010). Truncated b-amyloid peptide channels provide an alternative mechanism for Alzhiemer's disease and Down syndrome. PNAS 107: 6538-6543.
75. Jang H, Arce FT, Mustata M, et al. (2011). Antimicrobial protegrin-1 forms amyloid-like fibrils with rapid kinetics suggesting a functional link. Biophys J 100: 1775-1783.
76. Jang H, Connelly L, Arce FT, et al. (2013). Mechanisms for the insertion of toxic, fibril-like b-amyloid oligomers into the membrane. Chem Theory Comput 9: 822-833.
77. Ji SR, Wu Y, Sui, SF. (2002). Study of beta-amyloid peptide (Abeta40) insertion into phosphlipid membranes using monolayer technique. Biochem (Mosc) 67: 1283-1288.
78. JPK Instruments. (2005). The NanoWizard AFM Handbook, Version 1.3:3. Available from: www.jpk.com, tutorials.
79. Kagan BL, Hirakura Y, Azimov, R, et al. (2002). The channel hypothesis of Alzheimer's disease: Current status. Peptides 23: 1311-1315.
80. Kakio A, Nishimoto S, Yanagisawa K, et al. (2002). Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: Importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 41: 7385-7890.
81. Kakio A, Nishimoto S, Kozutsumi Y, Matsuzaki, K. (2003). Formation of membrane-active form of amyloid beta-protein in raft-like model membranes. Biochem Biophys Res Commun 303: 514-518.
82. Kayed R, Head E, Thompson JL, et al. (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489.
83. Kayed R, Sokolov Y, Edmonds B, et al. (2004). Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 279: 46363-46366.
84. Kayed R, Pensalfini A, Margol L, et al. (2009). Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem 284: 4230-4237.
85. Kinnunen PKJ. (2009). Amyloid formation on lipid membrane surfaces. Open Biol J 2: 163-175.
86. Knopman DS, DeKosky ST, Cummings JL, et al. (2001). Practice parameter: Diagnosis of dementia (an evidence-based review). Neurology 56: 1143-1153.
87. Kojro E, Gimpl G, Lammich S, et al. (2001). Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. PNAS 98: 5815-5820.
88. Koudinov AR, Berezov TT, Koudinova NV. (1998). Alzheimer's amyloid beta and lipid metabolism: A missing link? FASEB J 12: 1097-1099.
89. Kowalewski T, Holtzman DM. (1999). In situ atomic force microscopy study of Alzheimer's b-amyloid peptide on different substrates: New insights into mechanism of b-sheet formation. Proc Natl Acad Sci USA 96: 3688-3693.
90. Kremer JJ, Pallitto MM, Sklansky DJ, Murphy RM. (2000). Correlation of beta-amyloid aggregate size and hydrophobicity with decreased bilayer fluidity of model membranes. Biochemistry 39: 10309-10318.
91. Kuo YM, Emmerling MR, Vigo-Pelfrey C, et al. (1996). Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271: 4077-4081.
92. Kusomoto Y, Lomakin A, Teplow DB, Benedek GB. (1998). Temperature dependence of amyloid b-protein fibrillization. PNAS 95: 12277-12282.
93. Lal R, Arnsdorf MF. (2010). Multidimensional atomic force microscopy for drug discovery: A versatile tool for defining targets, designing therapeutics and monitoring their efficacy. Life Sci 86: 545-562.
94. Lansbury Jr PT. (1997). Inhibition of amyloid formation: A strategy to delay the onset of Alzheimer's disease. Curr Opin Chem Biol 1: 260-267.
95. Leonenko Z, Rodenstein M, Döner J, et al. (2006). The electrical surface potential of pulmonary surfactant. Langmuir 22: 10135-10139.
96. Levine H III. (1995). Soluble multimeric Alzheimer beta(1-40) preamyloid complexes in dilute solution. Neurobiol Aging 16: 755-764.
97. Lin H, Bhatia R, Lal R. (2001). Amyloid b protein forms ion channels: implications for Alzheimer's diseases pathophysiology. FASEB J 15: 2433-2444.
98. Lingwood D, Simons K. (2010). Lipid rafts as a membrane-organizing principle. Science 327: 46-50.
99. Linse S, Cabaleiro-Lago C, Xue W, et al. (2007). Nucleation of protein fibrillation by nanoparticles. PNAS 104: 8691-8696.
100. Lipowski R. (1995).Structure and dynamics of membranes - From cells to vesicles 1-65. North-Holland, Amsterdam: Elsevier.
101. Loo DT, Copani A, Pike CJ, et al. (1993). Apoptosis is induced by b-amyloid in cultured central nervous system neurons. PNAS 90: 7951-7955.
102. Maltseva E, Kerth A, Blume A, et al. (2005). Adsorption of amyloid b (1-40) peptide at phospholipid monolayers. ChemBioChem 6: 1817-1824.
103. Masters CL, Simms G, Weinman NA, et al. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. PNAS 82:4245-4249.
104. Mastrangelo IA, Ahmed M, Sato T, et al. (2006). High-resolution atomic force microscopy of soluble Abeta42 oligomers. J Mol Biol 358:106-119.
105. Mattson MP. (2004). Pathways towards and away from Alzheimer's disease. Nature 430: 631-639.
106. McMasters MJ, Hammer RP, McCarley RL. (2005). Surface-induced aggregation of beta amyloid peptide by co-substituted alkanethiol monolayers supported on gold. Langmuir 21: 4464-4470.
107. McMullen TPW, Lewis RNAH, McElhaney, RN. (2004). Cholesterolphospholipid interactions, the liquid-ordered phase and lipid rafts in model and biological membranes. Cur Opin Colloid Interface Sci 8: 459-468.
108. Moores B, Drolle E, Attwood SJ, et al. (2011). Effect of surfaces on amyloid fibril formation. PLoS ONE 6:e25954.
109. Muller WE, Eckert GP, Scheuer K, et al. (1998). Effects of beta-amyloid peptides on the fluidity of membranes from frontal and parietal lobes of human brain. High potencies of A beta 1-42 and A beta 1-43. Amyloid 5: 10-15.
110. Mutisya EM, Bowling AC, Beal MF. (1994). Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 63: 2179-2184.
111. Norlin N, Hellberg M, Filippov A, et al. (2012). Aggregation and fibril morphology of the Arctic mutation of Alzheimer's Ab peptide by CD, TEM, STEM and in situ AFM. J Struct Biol 180: 174-189.
112. O'Brien RJ, Wong PC. (2011). Amyloid precursor protein processing and Alzheimer's disease. Ann Rev Neurosci 34: 185-204.
113. Ohvo-Rekila H, Ramstedt B, Leppimaki P, Slotte J. (2002). Cholesterol interactions with phospholipids in membranes. Prog Lipid Res 41: 66-97.
114. Ono K, Condron MM, Teplow DB. (2009). Structure-neurotoxicity relationships of amyloid beta-protein oligomers. PNAS 106: 14745-14750.
115. Paravastu A, Leapman R, Yau W, Tycko R. (2008). Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. PNAS 105: 18349-18354.
116. Petkova AT, Leapman RD, Guo Z, Yau W-M, Mattson MP, Tycko R. (2005). Self-propagating, molecular-level polymorphism in Alzheimer's b-amyloid fibrils. Science 307: 262-265.
117. Poojari C, Kukol A, Strodel B. (2013). How the amyloid-b peptide and membranes affect each other: An extensive simulation study. Biochim Biophys Acta Biomem 1828: 327-339.
118. Powers ET, Kelly JW. (2001). Medium-dependent self-assembly of an amphiphilic peptide: direct observation of peptide phase domains at the air-water interface. J Am Chem Soc 123: 775-776.
119. Pronchik J, He X, Giurleo JT, Talaga DS. (2010). In vitro formation of amyloid from alpha-synuclein is dominated by reactions at hydrophobic interfaces. J Am Chem Soc 132: 9797-9803.
120. Pannuzzo M, Milardi D, Raudino A, et al. (2013). Analytical model and multiscale simulations of Ab peptide aggregation in lipid membranes: Towards a unifying description of conformational transitions, oligomerization and membrane damage. Phys Chem Chem Phys 15: 8940-8951.
121. Qin Z, Hu D, Zhu M, Fink AL. (2007). Structural characterization of the partially folded intermediates of an immunoglobulin light chain leading to amyloid fibrillation and amorphous aggregation. Biochemistry 46: 3521-3531.
122. Qiu L, Buie C, Reay A, et al. (2011). Molecular dynamics simulations reveal the protective role of cholesterol in beta-amyloid proteininduced membrane disruptions in neuronal membrane mimics. J Phys Chem B 115: 9795-9812.
123. Quist A, Doudevski I, Lin H, et al. (2005). Amyloid ion channels: A common structural link for protein-misfolding disease. PNAS 102: 10427-10432.
124. Quist A, Chand A, Ramachandran S, et al. (2007). Atomic force microscopy imaging and electrical recording of lipid bilayers supported over microfabricated silicon chip nanopores: Lab-on-achip system for lipid membranes and ion channels. Langmuir 23: 1375-1380.
125. Radmacher M. (2007). Studying the mechanics of cellular processes by atomic force microscopy. Methods Cell Biol 83: 347-372.
126. Rauk A. (2009). The chemistry of Alzheimer's disease. Chem Soc Rev 38: 2698-2715.
127. Refolo L, Malester B, LaFrancois J, et al. (2000). Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7: 321-331.
128. Relini A, Cavalleri O, Rolandi R, Gliozzi A. (2009). The two-fold aspect of the interplay of amyloidogenic proteins with lipid membranes. Chem Phys Lip 158: 1-9.
129. Ridgley DM, Barone JR. (2013). Evolution of the amyloid fiber over multiple length scales. ACS Nano 7: 1006-1015.
130. Rocha S, Krastev R, Thunemann AF, et al. (2005). Adsorption of amyloid b-peptide at polymer surfaces: a neutron reflectivity study. Chemphyschem 6: 2527-2534.
131. Roher AE, Chaney MO, Kuo YM, et al. (1996). Morphology and toxicity of Abeta-(1-42) dimer derived from neurotic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 271: 20631-20635.
132. Ryan T, Friedhube A, Lind M, et al. (2012). Small amphipathic molecules modulate secondary structure and amyloid fibril-forming kinetics of alzheimer disease peptide A-beta 1-42. J Biol Chem 287: 16947-16954.
133. Sabaté R, Espargaró A, Barbosa-Barros, L, et al. (2012). Effect of the surface charge of artificial model membranes on the aggregation of amyloid beta-peptide. Biochimie 94: 1730-1738.
134. Sasahara K, Morigaki K, Shinya K. (2013). Effects of membrane interaction and aggregation of amyloid b-peptide on lipid mobility and membrane domain structure. Phys Chem Chem 15: 8929-8939.
135. Sayre LM, Perry G, Smith MA. (1999). Redox metals and neurodegenerative disease. Curr Opin Chem Biol 3: 220-225.
136. Segers-Nolten I, van der Werf K, van Raaij M, Subramaniam V. (2007). Quantitative characterization of protein nanostructures using atomic force microscopy. Conf Proc IEEE Eng Med Biol Soc 2007: 6609-6612.
137. Selkoe DJ. (1980). Altered protein composition of isolated human cortical neurons in Alzheimer disease. Ann Neurol 8: 468-478.
138. Selkoe DJ. (1991). The molecular pathology of Alzheimer's disease. Neuron 6: 487-498.
139. Sepulveda J, Parodi RW, Peoples C, et al. (2010). Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. PLoS ONE 5:e11820.
140. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. (2011). Neuropathological alternation in Alzheimer disease. Cold Spring Harbor Perspect Med 1:a006189. doi: 10.1101/cshperspect.a006189.
141. Sharp JS, Forrest JA, Jones RA. (2002). Surface denaturation and amyloid fibril formation of insulin at model lipid-water interfaces. Biochemistry 41: 15810-15819.
142. Sheikh K, Giordani C, McManus J, et al. (2012). Differing modes of interaction between monomeric Ab 1-40 peptides and model lipid membranes: An AFM study. Chem Phys Lipids 165: 142-150.
143. Shen L, Adachi T, Bout DV, Zhu X. (2012). A mobile precursor determines amyloid-b peptide fibril formation at interfaces. J Am Chem Soc 134: 14172-14178.
144. Shulga N, Wilson-Smith R, Pastorino JG. (2009). Hexokinase II detachment from the mitochondria potentiates cisplatin induced cytotoxicity through a caspase-2 dependent mechanism. Cell Cycle 8: 3355-3364.
145. Sipe JD, Benson MD, Buxbaum JN, et al. (2010). Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 17: 101-104.
146. Soscia SJ, Kirby JE, Washicosky KJ, et al. (2010). The Alzheimer's disease-associated amyloid b-protein is an antimicrobial peptide. PLoS ONE 5:e5905.
147. Sokolov Y, Kozak JA, Kayed R, et al. (2006). Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol 128: 637-647.
148. Stefani M. (2012). Structural features of cytotoxicity of amyloid oligomers: Implications in Alzheimer's disease and other diseases with amyloid deposits. Prog Neurobiol 99: 226-245.
149. Stine WB, Snyder SW, Ladror US, et al. (1996). The nanometer-scale structure of amyloid-beta visualized by atomic force microscopy. J Protein Chem 15: 193-203.
150. Stine WB, Dahlgren KN, Krafft GA, LaDu MJ. (2002). In vitro characterization of conditions for amyloid-b peptide oligomerization and fibrillogenesis. J Biol Chem 278: 11612-11622.
151. Tanzi RE, McClatchey AI, Lamperti ED, et al. (1988). Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. Nature 331: 528-530.
152. Terzi E, Holzemann G, Seelig J. (1995). Self-association of beta-amyloid peptide (1-40) in solution and binding to lipid membranes. J Mol Biol 252: 633-642.
153. Thinnes FP, Gotz H, Kayser H, et al. (1989). Identification of human porins. I. Purification of a porin from human B-lymphocytes (Porin 31HL) and the topochemical proof of its expression on the plasmalemma of the progenitor cell. Biol Chem Hoppe-Seyler 370: 1253-1264.
154. Tofoleanu F, Buchete NV. (2012). Alzheimer Ab peptide interactions with lipid membranes: Fibrils, oligomers and polymorphic amyloid channels. Prion 6: 339-345.
155. Uversky VN, Li J, Fink AL. (2001). Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 276: 10737-10744.
156. Verdier Y, Penke B. (2004). Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer's disease. Curr Protein Peptide Sci 5: 19-31.
157. Walsh DM, Klyubin I, Fadeeva JV, et al. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal longterm potentiation in vivo. Nature 416: 535-539.
158. Walsh DM, Selkoe DJ. (2004). Oligomers on the brain: The emerging role of soluble protein aggregates in neurodegeneration. Protein Peptide Lett 11: 213-228.
159. Wang Q, Walsh DM, Rowan MJ, et al. (2004). Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogenactivated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24: 3370-3378.
160. Wang Q, Zhao J, Yu Z, et al. (2010). Alzheimer Abeta(1-42) monomer adsorbed on the self-assembled monolayers. Langmuir 26: 12722-12732.
161. Wang Z, Zhou C, Wang C, et al. (2003). AFM and STM study of b-amyloid aggregation on graphite. Ultramicroscopy 97: 73-79.
162. Wells K, Farooqui AA, Liss L, Horrocks LA. (1995). Neural membrane phospholipids in Alzheimer's disease. Neurochem Res 20: 1329-1333.
163. Williams T, Johnson B, Urbanc B, et al. (2011). Ab42 oligomers, but not fibrils, simultaneously bind to and cause damage to gangliosidecontaining lipid membranes. Biochem J 439: 67-77.
164. Williamson R, Usardi A, Hanger D, Anderton, B. (2008). Membranebound b-amyloid oligomers are recruited into lipid rafts by a fyndependent mechanism. FASEB J 22: 1552-1559.
165. Yamaguchi T, Yagi H, Goto Y, et al. (2010). A disulfide-linked amyloid-b peptide dimer forms a protofibril-like oligomer through a distinct pathway from amyloid fibril formation. Biochemistry 49: 7100-7107.
166. Yanagisawa K, Odaka A, Suzuki N, Ihara Y. (1995). GM1 gangliosidebound amyloid beta-protein (A beta): A possible form of preamyloid in Alzheimer's disease. Nature Med 1: 1062-1066.
167. Yang T, Hong S, O'Malley T, et al. (2013). New ELISAs with high specificity for soluble oligomers of amyloid b-protein detect natural Ab oligomers in human brain but not CSF. Alzheimer's Dementia 9: 99-112.
168. Yip CM, Elton EA, Darabie AA, et al. (2001). Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis and neurotoxicity. J Mol Biol 311: 723-734.
169. Yokoyama K, Welchons DR. (2007). The conjugation of amyloid beta protein on the gold colloidal nanoparticles' surfaces. Nanotechnology 18:105101.
170. Yu X, Wang Q, Lin Y, et al. (2012). Structure, orientation, and surface interaction of Alzheimer amyloid-b peptides on the graphite. Langmuir 28: 6595-6605.
171. Yu X, Zheng J. (2012). Cholesterol promotes the interaction of Alzheimer b-amyloid monomer with lipid bilayer. J Mol Biol 421: 561-571.
172. Zampagni M, Evangelisti E, Cascella R, et al. (2010). Lipid rafts are primary mediators of amyloid oxidative attack on plasma membrane. J Mol Med 88: 597-608.
173. Zerweck U, Loppacher C, Otto T, et al. (2005). Accuracy and resolution limits of Kelvin probe force microscopy. Phys Rev B 71: 125424-125433.
174. Zhao L, Long H, Mu Y, Yue Chew L. (2012). The toxicity of amyloidbeta oligomers. Int J Mol Sci 13: 7303-7327.
175. Zhu M, Souillac PO, Ionescu-Zanetti C, et al. (2002). Surface-catalyzed amyloid fibril formation. J Biol Chem 277: 50914-50922.